Gallic Acid Decreases Inflammatory Cytokine Secretion Through Histone Acetyltransferase/Histone Deacetylase Regulation in High Glucose-Induced Human Monocytes

Journal of Medicinal Food

Volumn 18, Issue 7, 2015, Pages 793-801

  Lee, Wooje ^a   Lee, Sang Yeol ^b   Son, Young Jin ^c   Yun, Jung Mi ^d  

^a Samsung Medical Center   (South Korea)

^b Gachon University   (South Korea)

^c Sunchon National University   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

diabetes; epigenetics; gallic acid; proinflammatory cytokine

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GALLIC ACID; GLUCOSE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CREBBP PROTEIN, HUMAN; CYTOKINE; HISTONE ACETYLTRANSFERASE PCAF;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; REGULATORY MECHANISM; UPREGULATION; WESTERN BLOTTING; ACETYLATION; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HYPERGLYCEMIA; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS);

ACETYLATION; CELL LINE; CREB-BINDING PROTEIN; CYTOKINES; EPIGENESIS, GENETIC; GALLIC ACID; GENE EXPRESSION; GLUCOSE; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; HYPERGLYCEMIA; INFLAMMATION; MONOCYTES; NF-KAPPA B; P300-CBP TRANSCRIPTION FACTORS;

EID: 84933511317     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2014.3342     Document Type: Article

References (61)

1. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
2. Pugliese G, Tilton RG, Williamson JR: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1991;7:35-59.
3. Ruderman N, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J 1992;6:2905-2914.
4. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: Advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008;4:285-293.
5. Igarashi M, Wakasaki H, Takahara N, et al.: Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999;103:185-195.
6. Yun JM, Jialal I, Devaraj S: Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem 2011;22:450-458.
7. Yun JM, Chien A, Jialal I, Devaraj S: Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: Mechanistic insights. J Nutr Biochem 2012;23:699-705.
8. Kang GL: The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79:1527-1534.
9. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP: Diabetes mellitus and inflammation. Curr Diab Rep 2013;13:435-444.
10. Muller S, Martin S, Koenig W: Impaired glucose tolerance is associated with increased serum concentrations of interlukin 6 and co-regulated acute proteins but not TNF-alpha or its receptors. Diabetologia 2002;45:805-812.
11. Devaraj S, Glaser N, Griffen S, et al.: Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774-779.
12. Devaraj S, Cheung AT, Jialal I, et al.: Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007;56:2790-2796.
13. Miao F, Gonzalo IG, Lanting L, Natarajan R: In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004;279:18091-18097.
14. Lin L, Li Y, Tollefsbol TO: Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 2008;10:25-36.
15. Rahman I, Marwick J, Kirkham P: Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol 2004;15:1255-1267.
16. Gray SG, De Meyts P: Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 2005;21:416-433.
17. Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120.
18. Lousia M, Natarajanm R: Epigenetics of diabetic complications. Expert Rev Endocrinol Metab 2010;5:137-148.
19. Glozak MA, Sengupta N, Zhang X, Seto E: Acetylyation and deacetylatoin of non-histone proteins. Gene 2005;363:15-23.
20. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-352.
21. Landrault N, Poucheret P, Ravel P, et al.: Antioxidant capacities and phenolic levels of French wines from different varieties and vintages. J Agric Food Chem 2001;49:3341-3348.
22. Ng TB, He JS, Niu SM, et al.: A gallic acid derivative and polysaccharides with antioxidative activity from Rose (Rosa rugosa) flowers. J Pharm Pharmacol 2004;56:537-545.
23. Kroes BH, van Berg AJ, Quarles van Ufford HC, van Dijk H, Labadie RP: Anti-inflammatory activity of gallic acid. Planta Med 1992;58:499-504.
24. Sohi K, Mittal N, Hundal MK, Khanduja KL: Gallic acid, an antioxidant, exhibits antiapoptotic potential in normal human lymphocytes: A Bcl-2 independent mechanism. J Nutr Sci Vitaminol (Tokyo) 2003;49:221-227.
25. Pellegrina CD, Padovani G, Mainente F, et al.: Anti-tumour potential of a gallic acid-containing phenolic fraction from Oenother biennis. Cancer Lett 2005;226:17-25.
26. Choi KC, Lee YH, Jung MG, et al.: Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol Cancer Res 2009;7:2011-2021.
27. Lu Z, Nie G, Belton PS, Tang H, Zhao B: Structure-activity relationship analysis of antioxidant ability and neuroprotective effect of gallic aicd derivatives. Neurochem Int 2006;48:263-274.
28. Umadevi S, Gopi V, Vellaichamy E: Inhibitory effect of gallic acid on advanced glycation end products induced up-regulation of inflammatory cytokines and matrix proteins in H9C2 (2-1) cells. Cardiovasc Toxicol 2013;3:396-405.
29. Punithavathi VR, Prince PS, Kumar R, Selvakumari J: Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats. Eur J Pharmacol 2011;650:465-471.
30. Punithavathi VR, Stanely Mainzen Prince P, Kumar MR, Selvakumari CJ: Protective effects of gallic acid on hepatic lipid peroxide metabolism, glycoprotein components and lipids in streptozotocin-induced type II diabetic Wistar rats. J Biochem Mol Toxicol 2011;25:68-76.
31. Patel SS, Goyal RK: Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats. Pharmacognosy Res 2011;3:239-245.
32. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000; 404: 787-790.
33. Perkins ND: Post-translational modifications regulating the activity and function of the nuclear factor κB pathway. Oncogene 2006;25:6717-6730.
34. Navarro-González JF, Mora-Fernández C: Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005;20:2601-2604.
35. Shanmugam N, Reddy MA, Guha M, Natarajan R: High-glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003;52:1256-1264.
36. Navarro-González JF, Mora-Fernández C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433-442.
37. Das ND, Jung KH, Park JH, et al.: Terminalia chebula extract acts as a potential NF-jB inhibitor in human lymphoblastic T cells. Phytother Res 2011;25:927-934.
38. Liu KY, Hu S, Chan BC, et al.: Anti-inflammatory and anti-allergic activities of Pentaherb formula, Moutan Cortex (Danpi) and gallic acid. Molecules 2013;25: 2483-2500.
39. Hsiang CY, Hseu YC, Chang YC, Kumar KJ, Ho TY, Yang HL: Toona sinensis and its major bioactive compound gallic acid inhibit LPS-induced inflammation in nuclear factor-κB transgenic mice as evaluated by in vivo bioluminescence imaging. Food Chem 2013;136:426-434.
40. Kim MJ, Seong AR, Yoo JY, et al.: Gallic acid, a histone acetyltransferase inhibitor, suppresses β-amyloid neurotoxicity by inhibiting microglial-mediated neuroinflammation. Mol Nutr Food Res 2011;55:1798-1808.
41. Kim SH, Jun CD, Suk K, et al.: Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci 2006;91:123-131.
42. Hogan S, Canning C, Sun S, Sun X, Zhou K: Effects of grape pomace antioxidant extract on oxidative stress and inflammation in diet induced obese mice. J Agric Food Chem 2010;58:11250-11256.
43. Kuppan G, Balasubramanyam J, Monickaraj F, et al.: Transcriptional regulation of cytokines and oxidative stress by gallic acid in human THP-1 monocytes. Cytokine 2010;49:229-234.
44. Bektas N, Ozturk Y: Effect of phenolic acids on functions of rat aorta, vas deferens and on metabolic changes in streptozotocin-induced diabetes. Indian J Pharmacol 2012;44:184-188.
45. Korani MS, Farbood Y, Sarkaki A, Fathi Moghaddam H, Taghi Mansouri M: Protective effects of gallic acid against chronic cerebral hypoperfusion-induced cognitive deficit and brain oxidative damage in rats. Eur J Pharmacol 2014 15;733:62-67.
46. Mansouri MT, Naghizadeh B, Ghorbanzadeh B, Farbood Y, Sarkaki A, Bavarsad K: Gallic acid prevents memory deficits and oxidative stress induced by intracerebroventricular injection of streptozotocin in rats. Pharmacol Biochem Behav 2013;111:90-96.
47. Ito K, Barnes P, Adcock IM: Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;2:6891-6903.
48. Guha M, Bai W, Nadler J, Natarajan R: Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000;275:17728-17739.
49. Barnes J, Karin M: Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
50. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:787-790.
51. Schmid H, Boucherot A, Yasuda Y, et al.: Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy. Diabetes 2006;55:2993-3003.
52. Cooper ME, El-Osta A: Epigenetics: Mechanisms and implications for diabetic complications. Circ Res 2010;107:1403-1413.
53. Cheung WL, Briggs SD, Allis CD: Acetylation and chromosomal functions. Curr Opin Cell Biol 2000;12:326-333.
54. Hayden MS, Ghosh S: Signaling to NF-κB. Genes Dev 2004;18:2195-2224.
55. El-Osta A, Brasacchio D, Yao D, et al.: Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normorglycemia. J Exp Med 2008;205:2409-2417.
56. Kurdistani SK, Grunstein M: Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003;4:276-284.
57. Yeung F, Hoberg JE, Ramsey CS, et al.: Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2360-2380.
58. Thompson PR, Wang D, Wang L, et al.: Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 2004;11:308-315.
59. Morimoto T, Sunagawa Y, Kawamura T, et al.: The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008;118:868-878.
60. Ho E, Clarke JD, Dashwood RH: Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 2009;139:2393-2396.
61. Link A, Balaguer F, Goel A: Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics. Biochem Pharmacol 2010;80:1771-1792.